Stayble Therapeutics AB (STABL) AI Stock Analysis

• Market Cap: kr15.93M
• Dividend Yield: N/A
• Average Volume (3M): 378.51K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.69
• Revenue Growth: N/A
• EPS Growth: 64.02%
• Country: SE
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 64,359,795
• 10 Day Avg. Volume: 398,578
• 30 Day Avg. Volume: 378,512
• PEG Ratio: 0.02
• Price to Book (P/B): 2.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.32
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: kr0.21 ▼(-13.75% Downside)

The score is held down primarily by weak financial performance (minimal revenue, large losses, and ongoing cash burn) and bearish technical trend signals (price below key moving averages with negative MACD). Valuation offers limited support because the company is loss-making (negative P/E) and no dividend yield is available.

Positive Factors

Modest Leverage

The company's low leverage reduces financial risk, providing a cushion against financial instability compared to peers with higher debt levels.

Improving Loss/Burn Rate

A reduced burn rate indicates better cost management, which can extend the company's runway and delay the need for additional funding.

Focused R&D Program

A focused R&D program on STA363 could lead to a breakthrough in treatment, providing a competitive edge in the spine-related disorders market.

Negative Factors

Minimal Revenue

Minimal revenue generation highlights the pre-commercial stage, posing a risk to financial sustainability and necessitating reliance on external funding.

High Negative ROE

A high negative ROE indicates poor returns to shareholders, suggesting ongoing dilution and financing challenges if losses continue.

Continued Cash Burn

Persistent negative cash flow reflects ongoing financial strain, necessitating external funding until the company achieves commercial success.

Stayble Therapeutics AB Business Overview & Revenue Model

Company Description

Stayble Therapeutics AB (STABL) is a clinical-stage pharmaceutical company based in Sweden that focuses on developing innovative treatments for degenerative disc disease and other musculoskeletal disorders. The company is primarily engaged in the research and development of non-surgical therapies that address the underlying causes of chronic back pain, offering potential relief and improved quality of life for patients.

How the Company Makes Money

Stayble Therapeutics AB generates revenue through the development and eventual commercialization of its proprietary treatment solutions for degenerative disc disease. The company primarily invests in clinical trials and research to bring its products to market, aiming to license its technologies to larger pharmaceutical companies upon successful trial results. Significant revenue streams are expected to arise from licensing agreements, milestone payments, and royalties from sales of approved therapies. Partnerships with research institutions and healthcare organizations may also contribute to its earnings by bolstering research capabilities and expanding market reach.

Stayble Therapeutics AB Financial Statement Overview

Summary

Stayble Therapeutics AB faces considerable financial challenges, primarily due to its inability to generate revenue while incurring high operating costs, leading to consistent net losses. The balance sheet shows financial solidity with no debt, but profitability metrics are weak. Overall, the company needs to improve its revenue generation and cost management to achieve financial sustainability.

Income Statement

Stayble Therapeutics AB has struggled to generate revenue, with a TTM revenue of $10,000, a significant increase from $0 in previous years. However, the company posts a substantial net loss of $12.4 million and negative EBIT and EBITDA margins, indicative of high operating expenses and limited revenue generation capacity within the biotechnology industry.

Balance Sheet

The balance sheet shows a strong equity base with a debt-to-equity ratio of 0, as the company has no debt. However, the equity ratio is 74.27%, reflecting financial stability. The company's ROE is negative, driven by significant net losses, which is concerning in terms of generating shareholder value.

Cash Flow

The company's cash flow statement indicates significant negative operating cash flow of $14.7 million TTM. Free cash flow is also negative, reflecting cash outflows that are not being offset by operating income. The operating cash flow to net income ratio is unfavorably negative, highlighting cash consumption without corresponding revenue generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	22.00K	0.00	0.00	0.00	0.00	0.00
Gross Profit	22.00K	-148.21K	0.00	0.00	0.00	0.00
EBITDA	-6.49M	-12.22M	309.41K	-24.50M	-12.03M	-15.09M
Net Income	-8.42M	-12.42M	-23.74M	-24.53M	-12.04M	-15.49M
Balance Sheet
Total Assets	9.90M	9.26M	21.70M	19.15M	43.64M	18.00M
Cash, Cash Equivalents and Short-Term Investments	3.80M	2.19M	14.08M	12.85M	37.47M	10.87M
Total Debt	850.00K	850.00K	850.00K	850.00K	850.00K	850.00K
Total Liabilities	1.44M	2.38M	5.19M	3.87M	3.83M	2.45M
Stockholders Equity	8.46M	6.87M	16.51M	15.28M	39.81M	15.55M
Cash Flow
Free Cash Flow	-6.78M	-14.67M	-23.54M	-24.89M	-9.63M	-23.98M
Operating Cash Flow	-6.78M	-14.67M	-23.54M	-24.89M	-9.63M	-23.98M
Investing Cash Flow	0.00	0.00	0.00	1.00K	-1.00K	0.00
Financing Cash Flow	6.99M	2.78M	24.96M	1.00K	36.15M	31.19M

Stayble Therapeutics AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.24
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:STABL, the sentiment is Positive. The current price of 0.24 is below the 20-day moving average (MA) of 0.25, above the 50-day MA of 0.23, and below the 200-day MA of 0.36, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 52.78 is Neutral, neither overbought nor oversold. The STOCH value of 77.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:STABL.

Stayble Therapeutics AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FLUI	46 Neutral	kr13.87M	-1.45	-45.97%	―	―	―
LARK	43 Neutral	kr44.35M	-1.01	―	8.47%	-94.12%	-25.83%
STABL	42 Neutral	kr15.93M	-1.34	-91.33%	―	―	64.02%
LIDDS	42 Neutral	kr5.84M	-0.83	-132.58%	―	―	86.26%